Related Experiment Video
Updated: Feb 4, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
1.5K
Etrasimod: A Next-Generation S1P Receptor Modulator for Ulcerative Colitis - Mechanistic Insights and Clinical
Manoj R Kumbhare1, Arshad S Shaikh1, Bhagwan R Ide1
1Department of Pharmaceutical Chemistry, SMBT College of Pharmacy (affiliated with Savitribai Phule Pune University), Dhamangaon, Nashik, Maharashtra 422403, India.
Summary
Etrasimod, a novel oral sphingosine-1-phosphate (S1P) receptor modulator, shows promise for treating ulcerative colitis (UC) by reducing inflammation with fewer risks. Clinical trials demonstrate its efficacy in improving remission and healing, offering a patient-friendly option.
Area of Science:
- Immunology
- Pharmacology
- Gastroenterology
Background:
- Immune-mediated inflammatory diseases (IMIDs) like ulcerative colitis (UC) require effective treatments.
- Selective sphingosine-1-phosphate (S1P) receptor modulators offer a targeted approach to immune modulation.
- First-generation S1P modulators have limitations in safety and patient adherence.
Purpose of the Study:
- To evaluate etrasimod, a next-generation S1P receptor modulator, as a treatment for moderate-to-severe UC.
- To assess the safety, efficacy, and pharmacokinetic profile of etrasimod compared to existing therapies.
- To explore the potential of etrasimod in managing other IMIDs.
Main Methods:
- Clinical trials (ELEVATE UC 12 and ELEVATE UC 52) were conducted to assess etrasimod's efficacy.
- Etrasimod's mechanism involves acting on S1PR1, S1PR4, and S1PR5 to retain lymphocytes.
- Comparisons were made against placebo and first-generation S1P modulators.
Main Results:
- Etrasimod demonstrated significant improvements in clinical remission and mucosal healing in UC patients.
- The drug exhibited a favorable safety profile and pharmacokinetic characteristics.
- A short washout period and once-daily oral dosing enhance patient adherence and convenience.
Conclusions:
- Etrasimod represents a significant advancement in UC management, offering targeted immune modulation.
- Its favorable safety and efficacy profile suggest potential for broader application in other IMIDs.
- The oral, once-daily formulation improves patient-friendliness and treatment adherence.
Keywords:
EtrasimodImmune-mediated inflammatory diseasesPharmacokineticsSafety profileSphingosine-1-phosphate receptor modulatorTargeted immunomodulationUlcerative colitisMore Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
519
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
519
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
991
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
991
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
596
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
596
01:31Internal Receptors
74.7K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.7K
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
998
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
998
01:28Peptic Ulcer Disease II: Pathophysiology
2.1K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.1K